Technical Analysis for ACRS - Aclaris Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 13.73 | -2.28% | -0.32 |
ACRS closed down 2.28 percent on Monday, February 6, 2023, on 2.55 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Earnings due: Feb 22
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Calm After Storm | Range Contraction | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Lower Bollinger Band Walk | Weakness | 0.00% | |
MACD Bearish Centerline Cross | Bearish | -2.28% | |
Volume Surge | Other | -2.28% | |
Stochastic Reached Oversold | Weakness | -2.28% | |
Gapped Up | Strength | -2.28% | |
Below Lower BB | Weakness | -2.28% | |
Lower Bollinger Band Touch | Weakness | -2.28% | |
Oversold Stochastic | Weakness | -2.28% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
Possible NR7 | about 3 hours ago |
60 Minute Opening Range Breakdown | about 5 hours ago |
3x Volume Pace | about 7 hours ago |
2x Volume Pace | about 7 hours ago |
1.5x Volume Pace | about 7 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/22/2023
Aclaris Therapeutics, Inc., a clinical-stage specialty pharmaceutical company, focuses on identifying, developing, and commercializing topical drugs to address various unmet needs in dermatology. Its lead drug candidate is A-101, a hydrogen peroxide topical solution that has completed three Phase II clinical trials for the treatment of seborrheic keratosis (SK), a common non-malignant skin tumor. The company is also developing A-101 as a prescription treatment for common warts; and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts. Aclaris Therapeutics, Inc. was founded in 2012 and is headquartered in Malvern, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Pharmaceutical Chemical Substances Hydrogen Dermatology Stage Specialty Pharmaceutical Hydrogen Peroxide Topical Medication Common Warts Keratosis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Pharmaceutical Chemical Substances Hydrogen Dermatology Stage Specialty Pharmaceutical Hydrogen Peroxide Topical Medication Common Warts Keratosis
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 18.9583 |
52 Week Low | 9.84 |
Average Volume | 427,309 |
200-Day Moving Average | 15.36 |
50-Day Moving Average | 16.05 |
20-Day Moving Average | 16.55 |
10-Day Moving Average | 16.03 |
Average True Range | 1.09 |
RSI | 31.97 |
ADX | 20.07 |
+DI | 15.95 |
-DI | 26.41 |
Chandelier Exit (Long, 3 ATRs) | 15.27 |
Chandelier Exit (Short, 3 ATRs) | 16.68 |
Upper Bollinger Bands | 18.85 |
Lower Bollinger Band | 14.25 |
Percent B (%b) | -0.11 |
BandWidth | 27.83 |
MACD Line | -0.35 |
MACD Signal Line | 0.04 |
MACD Histogram | -0.3884 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 14.87 | ||||
Resistance 3 (R3) | 14.89 | 14.53 | 14.68 | ||
Resistance 2 (R2) | 14.53 | 14.24 | 14.52 | 14.62 | |
Resistance 1 (R1) | 14.13 | 14.06 | 13.95 | 14.11 | 14.55 |
Pivot Point | 13.77 | 13.77 | 13.68 | 13.76 | 13.77 |
Support 1 (S1) | 13.37 | 13.48 | 13.19 | 13.35 | 12.91 |
Support 2 (S2) | 13.01 | 13.30 | 13.00 | 12.84 | |
Support 3 (S3) | 12.61 | 13.01 | 12.78 | ||
Support 4 (S4) | 12.59 |